awmsg logo



raltegravir (Isentress®)


Reference No. 254

Publication date:
25/11/2008


Appraisal information

raltegravir (Isentress®) 400 mg film-coated tablet


Company: Merck Sharp & Dohme Ltd
BNF category: Infections
NMG meeting date: 17/09/2008
AWMSG meeting date: 15/10/2008
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1808
Ministerial ratification: 18/11/2008

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Raltegravir (Isentress®) is recommended as an option for use within NHS Wales for the treatment of HIV-1 infection in treatment-experienced adults in accordance with British HIV Association (BHIVA) guidance. Raltegravir (Isentress®) is not suitable for shared care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download